Indian Army Pharmaceutical Procurement for Essential Cancer and Hormone Therapies

This tender, originating from the Department of Military Affairs within the Ministry of Defence, Government of India, is issued by the Indian Army, specifically for the procurement of a comprehensive range of high-value pharmaceutical products. Designated by Bid Number GEM/2026/B/8173384, this opportunity, dated October 23, 2026, commenced on the same day and will conclude on November 7, 2026, at 7:00 PM. The tender encompasses a substantial total quantity of 6,576 units across a diverse selection of critical medications. These include Enzalutamide 160 mg, Gefitinib 250 mg, Lenvatinib 10 mg, Acalbrutinib 100 mg, Everolimus 5 mg, Gimeracil 4.35mg plus Oteracil 11.8mg plus Tegafur 15 mg, Gimeracil 5.8 mg plus Oteracil 15.8 mg plus Tegafur 20 mg, Letrozole 2.5 mg, Exemestane 25 mg, Temozolamide 100 mg, Temozolamide 20 mg, Degarelix 80 mg injection, Trametinib 0.5 mg, Pomalidomide 2 mg, and Capecitabine 500 mg, as well as Afatinib 40 mg. The procurement is being managed by the Indian Army, with the specific office being identified as *********, located in Agra. This tender presents a significant opportunity for suppliers to contribute to the healthcare provisions of the Indian Army by furnishing these essential pharmaceutical supplies.